11/15
08:48 am
legn
Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think [Yahoo! Finance]
Medium
Report
Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think [Yahoo! Finance]
11/13
09:10 am
legn
Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $73.00 price target on the stock.
Medium
Report
Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $73.00 price target on the stock.
11/13
02:14 am
legn
Legend Biotech Corp (LEGN) Q3 2024 Earnings Call Highlights: CARVYKTI's Impressive Growth Amid ... [Yahoo! Finance]
Low
Report
Legend Biotech Corp (LEGN) Q3 2024 Earnings Call Highlights: CARVYKTI's Impressive Growth Amid ... [Yahoo! Finance]
11/12
11:02 am
legn
Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
Low
Report
Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
11/12
08:00 am
legn
Cellares Appoints Ossama Eissa, Former Novartis, Lonza and Legend Biopharma Leader, as Chief Operating Officer
Low
Report
Cellares Appoints Ossama Eissa, Former Novartis, Lonza and Legend Biopharma Leader, as Chief Operating Officer
11/12
07:00 am
legn
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
Low
Report
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
11/11
11:49 am
legn
Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
Low
Report
Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
11/11
07:23 am
legn
Legend Biotech Corp (LEGN) Q3 2024 Earnings Report Preview: What to Look For [Yahoo! Finance]
Low
Report
Legend Biotech Corp (LEGN) Q3 2024 Earnings Report Preview: What to Look For [Yahoo! Finance]
11/7
07:30 am
legn
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Low
Report
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
11/5
09:10 am
legn
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
Medium
Report
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
11/4
07:30 am
legn
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
Low
Report
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
10/29
10:19 am
legn
Legend Biotech Co. (NASDAQ: LEGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
Low
Report
Legend Biotech Co. (NASDAQ: LEGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
10/24
08:00 am
legn
Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
Low
Report
Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
10/24
05:57 am
legn
Global Biopharma Thought Leaders Gather in London: Join the 2024 GenScript Biotech Global Forum for Cutting-Edge Insights [Yahoo! Finance]
Low
Report
Global Biopharma Thought Leaders Gather in London: Join the 2024 GenScript Biotech Global Forum for Cutting-Edge Insights [Yahoo! Finance]
10/24
05:53 am
legn
Global Biopharma Thought Leaders Gather in London: Join the 2024 GenScript Biotech Global Forum for Cutting-Edge Insights
Low
Report
Global Biopharma Thought Leaders Gather in London: Join the 2024 GenScript Biotech Global Forum for Cutting-Edge Insights
10/16
08:31 am
legn
Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $73.00 price target on the stock.
Medium
Report
Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $73.00 price target on the stock.
10/16
05:43 am
legn
Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies
Low
Report
Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies
10/8
07:32 am
legn
Legend Biotech Co. (NASDAQ: LEGN) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $86.00 price target on the stock.
Low
Report
Legend Biotech Co. (NASDAQ: LEGN) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $86.00 price target on the stock.
10/3
07:30 am
legn
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
Low
Report
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
9/30
08:01 am
legn
Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $73.00 price target on the stock.
Medium
Report
Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $73.00 price target on the stock.
9/27
09:11 pm
legn
Frost & Sullivan Released Report: "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends"
Low
Report
Frost & Sullivan Released Report: "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends"
9/27
04:37 pm
legn
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line [Yahoo! Finance]
Low
Report
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line [Yahoo! Finance]
9/27
04:35 pm
legn
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
Low
Report
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
9/27
10:09 am
legn
Legend Biotech Co. (NASDAQ: LEGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
Low
Report
Legend Biotech Co. (NASDAQ: LEGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
9/24
09:00 am
legn
Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech
Low
Report
Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech